{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T17:38:03Z","timestamp":1795196283098,"version":"4.10.3"},"reference-count":34,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy","award":["2463\/09\/17.01.2020"],"award-info":[{"award-number":["2463\/09\/17.01.2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: The pathogenesis of MASLD (metabolic dysfunction-associated steatotic liver disease) is driven by environmental, genetic, metabolic, immune, and inflammatory factors. IL-17 and TLR4 determine hepatic steatosis, inflammation, and finally fibrosis. Objectives: To explore the associations between the plasma levels of inflammatory markers, TLR4, and the cytokines IL17A\/F, as well as their connections with the degree of hepatic steatosis and the risk of hepatic fibrosis (defined by the FIB-4 score) in MASLD patients. Methods: The study cohort included 80 patients diagnosed with MASLD. The IL-17A\/F and TLR4 serum concentrations were determined using the ELISA method. Results: We found a significant difference in the CAR levels (C-reactive protein to albumin ratio) when comparing MASLD patients with severe steatosis to those with mild\/moderate steatosis (Student\u2019s t test, t (71) = 2.32, p = 0.023). The PIV (pan-immune inflammatory value) was positively correlated with the SII (systemic immune inflammation index), (r = 0.86, p &lt; 0.0001) and the CAR (r = 0.41, p = 0.033) in MASLD patients with severe steatosis. In contrast, increased values of the LMR (lymphocyte to monocyte ratio) were significantly associated, with decreased levels of the SII (\u03c1 = \u22120.38, p = 0.045). We also found a positive correlation between the CAR and the SII (r = 0.41, p = 0.028). In patients with mild\/moderate steatosis, a significant positive correlation was observed between the SII and IL17A (r = 0.36, p = 0.010), the PIV and the CAR (r = 0.29, p = 0.011), the PIV and the SII (r = 0.87, p &lt; 0.0001) and the PIV and IL17A (r = 0.3, p = 0.036). A negative correlation was observed between the LMR and the SII (r = \u22120.55, p &lt; 0.0001) and the CAR and IL17F (r = \u22120.37, p = 0.011). Regarding the inflammatory markers, the PIV (336.4 vs. 228.63, p = 0.0107), and the SII (438.47 vs. 585.39, p = 0.0238) had significantly lower levels in patients with an intermediate\u2013high risk of hepatic fibrosis as compared with the patients with a low risk of hepatic fibrosis. The PNI (prognostic nutritional index) (47.16 vs. 42.41, p = 0.0392) had significantly different levels in patients with the likelihood of hepatic fibrosis than those with a low risk of hepatic fibrosis. Conclusions: Regarding the inflammatory markers, the PIV and the SII hold promise as biomarkers for discriminating between MASLD patients with an intermediate\u2013high risk and those with a low risk of hepatic fibrosis. Our findings underscore the role of IL-17A and its potential relationship with inflammatory markers in MASLD pathogenesis and the progression to hepatic fibrosis.<\/jats:p>","DOI":"10.3390\/biomedicines12092144","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T04:45:28Z","timestamp":1727066728000},"page":"2144","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Metabolic Dysfunction-Associated Steatotic Liver Disease: The Associations between Inflammatory Markers, TLR4, and Cytokines IL-17A\/F, and Their Connections to the Degree of Steatosis and the Risk of Fibrosis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0400-7296","authenticated-orcid":false,"given":"Sorina-Cezara","family":"Coste","sequence":"first","affiliation":[{"name":"4th Department of Internal Medicine, Faculty of Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga Hilda","family":"Or\u0103\u0219an","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, Faculty of Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Cozma","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, Faculty of Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasile","family":"Negrean","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, Faculty of Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela-Viviana","family":"Sitar-T\u0103ut","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, Faculty of Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7447-4925","authenticated-orcid":false,"given":"Gabriela Adriana","family":"Filip","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Embryology, Faculty of Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0944-3161","authenticated-orcid":false,"given":"Adriana Corina","family":"Hangan","sequence":"additional","affiliation":[{"name":"Department of Inorganic Chemistry, Faculty of Pharmacy, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-4760","authenticated-orcid":false,"given":"Roxana Liana","family":"Lucaciu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biochemistry and Clinical Laboratory, Faculty of Pharmacy, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4557-5364","authenticated-orcid":false,"given":"Mihaela","family":"Iancu","sequence":"additional","affiliation":[{"name":"11th Department of Medical Education, Medical Informatics and Biostatistics, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-5775","authenticated-orcid":false,"given":"Lucia Maria","family":"Procopciuc","sequence":"additional","affiliation":[{"name":"Department of Molecular Sciences, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.15403\/jgld-5518","article-title":"The New Nomenclature for Fatty Liver Disease","volume":"33","author":"Francque","year":"2024","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global Incidence of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of 63 Studies and 1,201,807 Persons","volume":"79","author":"Le","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current Status and Future Trends of the Global Burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-Liver Axis: Pathophysiological Concepts and Clinical Implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2567.2011.03465.x","article-title":"The Interleukin-17 Cytokine Family: Critical Players in Host Defence and Inflammatory Diseases","volume":"134","author":"Pappu","year":"2011","journal-title":"Immunology"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Abdelnabi, M.N., Hassan, G.S., and Shoukry, N.H. (2024). Role of the Type 3 Cytokines IL-17 and IL-22 in Modulating Metabolic Dysfunction-Associated Steatotic Liver Disease. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1437046"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/hep.26746","article-title":"IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice","volume":"59","author":"Harley","year":"2014","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccell.2016.05.020","article-title":"Metabolic Inflammation-Associated IL-17A Causes Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma","volume":"30","author":"Gomes","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The Role of Pattern-Recognition Receptors in Innate Immunity: Update on Toll-like Receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Yu, L., Gao, F., Li, Y., Su, D., Han, L., Li, Y., Zhang, X., and Feng, Z. (2024). Role of Pattern Recognition Receptors in the Development of MASLD and Potential Therapeutic Applications. Biomed. Pharmacother., 175.","DOI":"10.1016\/j.biopha.2024.116724"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"106507","DOI":"10.1016\/j.phrs.2022.106507","article-title":"Toll-like Receptors and Metabolic (Dysfunction)-Associated Fatty Liver Disease","volume":"185","author":"Khanmohammadi","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1755-1536-3-21","article-title":"Toll-like Receptor 4 Signaling in Liver Injury and Hepatic Fibrogenesis","volume":"3","author":"Guo","year":"2010","journal-title":"Fibrogenesis Tissue Repair"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chen, I.-T., Cheng, A.-C., Liu, Y.-T., Yan, C., Cheng, Y.-C., Chang, C.-F., and Tseng, P.-H. (2022). Persistent TLR4 Activation Promotes Hepatocellular Carcinoma Growth through Positive Feedback Regulation by LIN28A\/Let-7g miRNA. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158419"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.lfs.2017.04.025","article-title":"Toll like Receptor 4 and Hepatocellular Carcinoma; A Systematic Review","volume":"179","author":"Sepehri","year":"2017","journal-title":"Life Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jpedsurg.2017.03.026","article-title":"Toll-like Receptor 4 Is Critical for the Development of Resection-Associated Hepatic Steatosis","volume":"52","author":"Barron","year":"2017","journal-title":"J. Pediatr. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Androutsakos, T., Bakasis, A.-D., Pouliakis, A., Gazouli, M., Vallilas, C., and Hatzis, G. (2022). Single Nucleotide Polymorphisms of Toll-like Receptor 4 in Hepatocellular Carcinoma\u2014A Single-Center Study. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169430"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ortiz-L\u00f3pez, N., Fuenzalida, C., Dufeu, M.S., Pinto-Le\u00f3n, A., Escobar, A., Poniachik, J., Roblero, J.P., Valenzuela-P\u00e9rez, L., and Beltr\u00e1n, C.J. (2022). The Immune Response as a Therapeutic Target in Non-Alcoholic Fatty Liver Disease. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.954869"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and Resolution of Inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ye, Z., Hu, T., Wang, J., Xiao, R., Liao, X., Liu, M., and Sun, Z. (2022). Systemic Immune-Inflammation Index as a Potential Biomarker of Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.933913"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lin, F., Zhang, L.-P., Xie, S.-Y., Huang, H.-Y., Chen, X.-Y., Jiang, T.-C., Guo, L., and Lin, H.-X. (2022). Pan-Immune-Inflammation Value: A New Prognostic Index in Operative Breast Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.830138"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MEG.0000000000002686","article-title":"Association between Novel Inflammatory Markers and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study","volume":"36","author":"Wang","year":"2024","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_24","unstructured":"(2024, August 19). Available online: https:\/\/www.bsg.org.uk\/web-education\/nafld-%E2%80%93-diagnosis,-assessment-and-management."},{"key":"ref_25","unstructured":"(2024, August 19). Clinical Features and Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease (Nonalcoholic Fatty Liver Disease) in Adults\u2014UpToDate. Available online: https:\/\/www.uptodate.com\/contents\/clinical-features-and-diagnosis-of-metabolic-dysfunction-associated-steatotic-liver-disease-nonalcoholic-fatty-liver-disease-in-adults?source=history_widget#H8."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102393","DOI":"10.1016\/j.clinre.2024.102393","article-title":"The Pan Immune Inflammatory Value in Relation to Non-Alcoholic Fatty Liver Disease and Hepatic Fibrosis","volume":"48","author":"Jiang","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MPG.0b013e31821b4b61","article-title":"Ultrasonographic Quantitative Estimation of Hepatic Steatosis in Children With NAFLD","volume":"53","author":"Shannon","year":"2011","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_28","first-page":"1104","article-title":"Nash Clinical Research Network Comparison of Noninvasive Markers of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_29","first-page":"1","article-title":"Serum IL-17, Obesity, and Metabolic Risk in Mexican Young Adults","volume":"20","year":"2021","journal-title":"RESPYN Rev. Salud P\u00fablica Nutr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ijo.2008.216","article-title":"Increased Activity of Interleukin-23\/Interleukin-17 Proinflammatory Axis in Obese Women","volume":"33","author":"Stevanovic","year":"2009","journal-title":"Int. J. Obes."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1001\/jama.289.14.1799","article-title":"Effect of Weight Loss and Lifestyle Changes on Vascular Inflammatory Markers in Obese Women: A Randomized Trial","volume":"289","author":"Esposito","year":"2003","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1515\/jpem-2022-0494","article-title":"Role of Pan Immune Inflammatory Value in the Evaluation of Hepatosteatosis in Children and Adolescents with Obesity","volume":"35","year":"2022","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/jgh.12924","article-title":"Role of Serum Toll-like Receptors 2 and 4 in Non-alcoholic Steatohepatitis and Liver Fibrosis","volume":"30","author":"Cengiz","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_34","first-page":"569","article-title":"Hepatic Toll-like Receptor 4 Expression Is Associated with Portal Inflammation and Fibrosis in Patients with NAFLD","volume":"35","author":"Carotti","year":"2015","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/12\/9\/2144\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:01:51Z","timestamp":1760112111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/12\/9\/2144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,21]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["biomedicines12092144"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines12092144","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,21]]}}}